Novo Nordisk A/S
XBER:NOVA

Watchlist Manager
Novo Nordisk A/S Logo
Novo Nordisk A/S
XBER:NOVA
Watchlist
Price: 41.15 EUR 1.48% Market Closed
Market Cap: 139.4B EUR

Relative Value

The Relative Value of one NOVA stock under the Base Case scenario is 71.48 EUR. Compared to the current market price of 41.15 EUR, Novo Nordisk A/S is Undervalued by 42%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

NOVA Relative Value
Base Case
71.48 EUR
Undervaluation 42%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
98
vs Industry
18
Median 3Y
10.9
Median 5Y
9.9
Industry
2.6
Forward
4.7
vs History
96
vs Industry
21
Median 3Y
34.9
Median 5Y
29.4
Industry
21.7
Forward
14
vs History
98
vs Industry
23
Median 3Y
25.1
Median 5Y
23.1
Industry
16.7
vs History
93
vs Industry
24
Median 3Y
32.9
Median 5Y
24.5
Industry
23.1
vs History
98
vs Industry
3
Median 3Y
24.2
Median 5Y
20.2
Industry
2.2
vs History
98
vs Industry
16
Median 3Y
11
Median 5Y
9.9
Industry
2.9
Forward
4.9
vs History
98
vs Industry
22
Median 3Y
13.1
Median 5Y
11.9
Industry
5.5
vs History
96
vs Industry
25
Median 3Y
23.3
Median 5Y
21.4
Industry
13.2
Forward
10.1
vs History
96
vs Industry
25
Median 3Y
25.6
Median 5Y
23.4
Industry
16.8
Forward
11.6
vs History
98
vs Industry
23
Median 3Y
25
Median 5Y
23.1
Industry
15.9
vs History
95
vs Industry
15
Median 3Y
33.1
Median 5Y
29.7
Industry
19.2
vs History
98
vs Industry
13
Median 3Y
9.6
Median 5Y
8.7
Industry
1.9

Multiples Across Competitors

NOVA Competitors Multiples
Novo Nordisk A/S Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
DK
Novo Nordisk A/S
XBER:NOVA
1.5T EUR 4.7 14.2 9.9 11.6
US
Eli Lilly and Co
NYSE:LLY
1T USD 17.1 55.3 37.1 39.8
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
496.3B USD 5.4 19.8 16.2 21
CH
Roche Holding AG
SIX:ROG
262.9B CHF 4.3 27.9 11.9 13.9
UK
AstraZeneca PLC
LSE:AZN
212.8B GBP 4.9 30.5 109.1 159.7
CH
Novartis AG
SIX:NOVN
212.1B CHF 4.8 18.6 11.8 15.2
US
Merck & Co Inc
NYSE:MRK
260.5B USD 4.1 13.7 9.7 11.5
IE
Endo International PLC
LSE:0Y5F
209B USD 90.1 -71.5 331.1 830.4
US
Pfizer Inc
NYSE:PFE
143B USD 2.3 14.6 7.4 10.1
FR
Sanofi SA
PAR:SAN
100.2B EUR 1.5 7.3 6.6 6.6
P/E Multiple
Earnings Growth PEG
DK
Novo Nordisk A/S
XBER:NOVA
Average P/E: 22.4
14.2
4%
3.6
US
Eli Lilly and Co
NYSE:LLY
55.3
53%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
19.8
29%
0.7
CH
Roche Holding AG
SIX:ROG
27.9
29%
1
UK
AstraZeneca PLC
LSE:AZN
30.5
38%
0.8
CH
Novartis AG
SIX:NOVN
18.6
17%
1.1
US
Merck & Co Inc
NYSE:MRK
13.7
15%
0.9
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -71.5 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.6
29%
0.5
FR
Sanofi SA
PAR:SAN
7.3
26%
0.3
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
DK
Novo Nordisk A/S
XBER:NOVA
Average EV/EBITDA: 399.7
9.9
2%
5
US
Eli Lilly and Co
NYSE:LLY
37.1
33%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
16.2
9%
1.8
CH
Roche Holding AG
SIX:ROG
11.9
4%
3
UK
AstraZeneca PLC
LSE:AZN
109.1
10%
10.9
CH
Novartis AG
SIX:NOVN
11.8
6%
2
US
Merck & Co Inc
NYSE:MRK
9.7
6%
1.6
IE
E
Endo International PLC
LSE:0Y5F
331.1
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.4
1%
7.4
FR
Sanofi SA
PAR:SAN
6.6
8%
0.8
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
DK
Novo Nordisk A/S
XBER:NOVA
Average EV/EBIT: 1 711.1
11.6
1%
11.6
US
Eli Lilly and Co
NYSE:LLY
39.8
36%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
21
15%
1.4
CH
Roche Holding AG
SIX:ROG
13.9
5%
2.8
UK
AstraZeneca PLC
LSE:AZN
159.7
23%
6.9
CH
Novartis AG
SIX:NOVN
15.2
12%
1.3
US
Merck & Co Inc
NYSE:MRK
11.5
8%
1.4
IE
E
Endo International PLC
LSE:0Y5F
830.4
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.1
8%
1.3
FR
Sanofi SA
PAR:SAN
6.6
15%
0.4